Takeda's Takhzyro scores in Phase III study in preventing HAE attacks in young children

Japan’s largest drugmaker Takeda (TYO: 4502) has announced late-breaking data from the Phase III SPRING study presented at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2022, demonstrating positive results of Takhzyro (lanadelumab) for preventing hereditary angioedema (HAE) attacks in patients 2 to <12 years of age, which were consistent with earlier studies in adult and adolescent patients. There are currently no long-term prophylactic (LTP) treatments approved for HAE patients younger than six years.

The primary objective of the open-label, multicenter, Phase III SPRING study was to evaluate the safety and pharmacokinetics (PK) of Takhzyro in patients aged 2 to <12 years with HAE. Clinical outcomes (prevention of HAE attacks) were measured as a secondary objective.

“The SPRING study data reinforce the safety and efficacy of Takhzyro across a broad range of patients living with HAE,” said Ming Yu, global clinical lead, Takeda, adding; “We are encouraged by these findings as they demonstrate the potential of long-term prophylaxis treatments to reduce recurrent HAE attacks in children as young as two who currently have no approved long-term preventative treatment option.”